Advertisement

Durable Remissions With Brentuximab Vedotin in Patients With CD30-Positive Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Advertisement

Key Points

  • Among 48 patients with CD30-positive diffuse large B-cell lymphoma (DLBCL) who received brentuximab vedotin in a phase II, open-label study, 21 (44%) had objective responses.
  • Eight patients (17%) had complete remission, with a median duration of 16.6 months.
  • Responses occurred across a range of  CD30 expression.

A phase II, open-label study evaluating the efficacy of brentuximab vedotin (Adcetris), an anti-CD30 antibody-drug conjugate, found that among 48 evaluable patients with CD30-positive diffuse large B-cell lymphoma, 21 (44%) had objective responses. This total included 8 patients (17%) with complete remission and 13 (27%) with partial remission. “Complete remissions were durable, with a median duration of 16.6 months,” reported Jacobsen et al in Blood.

The planned subset analysis of B-cell non-Hodgkin lymphomas (NHLs) also included 19 patients with other B-cell NHLs. The median ages were 62 among patients with diffuse large B-cell lymphoma and 36 among patients with other B-cell lymphomas.

Eligible patients had any subtype of histologically confirmed B-cell lymphoma with detectable CD30 expression by visual assessment of immunohistochemistry, bidimensionally measurable disease of 1.5 cm in greatest transverse diameter, and no history of another active invasive malignancy in the previous 3 years. Most patients had stage III or IV disease. More than half of all patients had received at least three prior systemic therapies, and nearly all had received prior rituximab (Rituxan).

All patients received 1.8 mg/kg of brentuximab vedotin intravenously every 3 weeks, and those achieving stable disease or better could receive continued treatment until disease progression, unacceptable toxicity, or study closure. To assess the safety of brentuximab vedotin when given in combination with rituximab, a separate cohort of patients (planned n ≈ 15) received brentuximab vedotin 1.8 mg/kg intravenously in combination with rituximab (375 mg/m2) on day 1 of each 3-week cycle. Patients were treated at 26 sites in the United States.

Responses Across Range of CD30 Expression

“[Diffuse large B-cell lymphoma] patients were generally refractory to frontline (76%) and most recent therapies (82%), and 44% of these refractory patients responded (15% [complete remission]),” the investigators noted. Responses occurred across a range of CD30 expression. To further understand the activity of the study drug in patients with low levels of CD30 expression, the study was amended in July 2013 to evaluate the efficacy of monotherapy in diffuse large B-cell lymphoma patients with undetectable CD30 expression. Results from this cohort are forthcoming, the authors wrote.

Among patients with other B-cell lymphomas, there was one complete remission and two partial remissions among six patients with gray-zone NHL, one complete remission among six patients with primary mediastinal B-cell lymphoma, and one complete remission among three patients with post-transplant lymphoproliferative disorder.

“Brentuximab vedotin as a single agent and in combination with rituximab was generally well tolerated in these heavily pretreated patients with advanced disease,” the investigators noted, with adverse events consistent with known toxicities. Treatment-emergent adverse events occurring in ≥ 25% of B-cell patients treated with single-agent brentuximab vedotin included fatigue, diarrhea, neutropenia, nausea, decreased appetite, pyrexia, and peripheral sensory neuropathy. “All five deaths within 30 days of the last study treatment were disease related,” the authors stated.

Eric D. Jacobsen, MD, of Dana-Farber Cancer Institute, is the corresponding author of the Blood article.

The study was sponsored by Seattle Genetics. For full disclosures of the study authors, visit www.bloodjournal.org.

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.


Advertisement

Advertisement



Advertisement